David Chiswell, Ph.D.

Chairman of the Board, Albireo; Former Chief Executive Officer, Kymab; Non-Executive Chairman, IGEM Therapeutics; Board Member of Bond 2 Development 2 GP

After a career as a research scientist in both the United Kingdom and the United States and nine years working in scientific management at Amersham International, David Chiswell co-founded Cambridge Antibody Technology (CAT) and served as its CEO for several years. In addition to Albireo, Dr. Chiswell is currently CEO of Kymab Ltd.  

He was previously chairman of the UK’s BioIndustry Association (BIA) and remains on its board. In 2006, Dr. Chiswell was awarded the OBE by HM Queen for services to the biotechnology industry.

Team members

David Chiswell, Ph.D.

Chairman of the Board, Albireo; Former Chief Executive Officer, Kymab; Non-Executive Chairman, IGEM Therapeutics; Board Member of Bond 2 Development 2 GP

Anne Klibanski, M.D.

Laurie Carrol Guthart Professor of Medicine and Academic Dean for Partners, Harvard Medical School; Interim President and CEO, Partners HealthCare; Chief Academic Officer, Partners HealthCare

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics (retired)

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Davey S. Scoon

Chair of the Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer